Fosun Health Capital

Founded in 2019, Fosun Health Capital is a corporate venture capital firm based in Shanghai, China. The firm prefers to invest in biopharmaceutics and biotechnology sectors.

15 past transactions

Cellbri

Series B in 2025
Cellbri is a manufacturing company that produces and sells automated CGT industrial instruments for cell processing programs.

Celregen Therapeutics

Angel Round in 2025
Celregen Therapeutics is a pharmaceutical company specializing in the development of innovative cell therapy and regenerative medicine treatments. It offers advanced technologies such as rapid induced pluripotent stem cell (iPSC) reprogramming, a patented CRISPR/Cas12b-based iPSC gene-editing platform, and bioinformatics-guided differentiation techniques. These solutions cover the entire research and development process for iPSCs and their derived products, providing comprehensive upstream and downstream support.

Transcend Vivoscope

Series B in 2025
Transcend Vivoscope is a biotechnology company focused on advanced microscopy imaging products and solutions. It develops high-resolution microscopy imaging systems tailored to meet the needs of healthcare providers. These systems enable the creation of innovative imaging tools that support various fields, including 3D cell biology, neuroscience, developmental biology, and clinical medicine. Through its advanced technology, Transcend Vivoscope aims to enhance the capabilities of healthcare professionals in their diagnostic and research efforts.

Aiyi animal medicine

Series C in 2025
Aiyi Animal Medicine develops and produces veterinary biological products and veterinary chemical medications.

Jishi Medical

Seed Round in 2024
Jishi Medical is a med-tech company that specializes in the research and development of eye diseases and overall solutions for ophthalmology diagnosis and treatment.

Celregen Therapeutics

Seed Round in 2024
Celregen Therapeutics is a pharmaceutical company specializing in the development of innovative cell therapy and regenerative medicine treatments. It offers advanced technologies such as rapid induced pluripotent stem cell (iPSC) reprogramming, a patented CRISPR/Cas12b-based iPSC gene-editing platform, and bioinformatics-guided differentiation techniques. These solutions cover the entire research and development process for iPSCs and their derived products, providing comprehensive upstream and downstream support.

Shengbao Bio

Series A in 2024
Shengbao Bio is committed to the development of novel live bacterial medications, leveraging gene circuits and precise regulation of gene and payload expression.

Conjustar

Seed Round in 2024
Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients.

AIMIRA Innovation Technology

Seed Round in 2023
AIMIRA Innovation Technology is an AI-based medical technology company that offers diagnosis, aesthetic plastic surgery, and anti-aging medicine.

Atantares

Seed Round in 2023
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.

Boao Mingsai

Series B in 2023
Boao Mingsai is a biopharmaceutical company that focuses on the drug development.

Conjustar

Seed Round in 2023
Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients.

Chaomu Technology

Series A in 2022
Chaomu Technology is a high-tech research and development enterprise dedicated to solving difficult human eye diseases. The company provides medical intelligent high-tech equipment and solutions. The pursuit of super purpose is to alleviate the increasing sub-light suffering of eye disease patients worldwide in a more scientific manner and to realize the dream of returning hundreds of millions of eye disease patients to a bright world.

Thousand Oaks Biopharmaceuticals

Series C in 2021
Thousand Oaks Biopharmaceuticals, Inc., established in 2017 and headquartered in Haimen, China, specializes in contract development and manufacturing services for the biotechnology industry. The company focuses on developing technologies to produce protein and vaccine compounds, offering integrated control solutions that optimize processes, increase protein expression, and reduce production scale. Thousand Oaks provides personalized, chemically defined cell culture media, formula production, technical support, and ancillary services to its clients in the biopharmaceutical sector.

Boao Mingsai

Series A in 2020
Boao Mingsai is a biopharmaceutical company that focuses on the drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.